MOLECULIN BIOTECH, INC. (NASDAQ:MBRX) Files An 8-K Other Events

MOLECULIN BIOTECH, INC. (NASDAQ:MBRX) Files An 8-K Other Events
Item 8.01.Other Events.

On February 15, 2018, Moleculin Biotech, Inc., (the "Company") issued a press release announcing that, to its continued collaboration with MD Anderson it has developed and licensed what it believes is a major breakthrough in immune-stimulating STAT3 inhibitors. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.Description

99.1Press release dated February 15, 2018


Moleculin Biotech, Inc. Exhibit
EX-99.1 2 exh991-wp1066stat3.htm EXHIBIT 99.1 Exhibit Exhibit 99.1            Moleculin Announces Breakthrough Discovery of a New Molecule for Cancer TreatmentCutting Edge Science Suggests New Molecule is Capable of Shutting Down Tumor ActivityHOUSTON – February 15,…
To view the full exhibit click here

About MOLECULIN BIOTECH, INC. (NASDAQ:MBRX)

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations.

An ad to help with our costs